IgnacioGarrido LagunaMDPhD, MBA
Oncology • Salt Lake City, UTGastrointestinal Cancer
Professor at Huntsman Cancer Institute at the University of Utah
Dr. Garrido Laguna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1950 Circle of Hope Dr
# Clinic
Salt Lake City, UT 84112Phone+1 801-585-0255
Education & Training
David Eccles School of BussinesMBA, 2021 - 2023
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2011
Universidad de Navarra Faculty of MedicineClass of 2001
Certifications & Licensure
UT State Medical License 2011 - 2026
TX State Medical License 2009 - 2011- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
- European Union (RCPI)Medical Oncology
Clinical Trials
- A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer Start of enrollment: 2014 Jan 01
- Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Start of enrollment: 2014 Aug 01
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Start of enrollment: 2015 Nov 19
- Join now to see all
Publications & Presentations
PubMed
- Gemcitabine-induced myositis in a patient with pancreatic cancer.Zach Rubnitz, Chris Nevala-Plagemann, Vaia Florou, Ignacio Garrido-Laguna
BMJ Case Reports. 2025-01-21 - KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma.Carter Norton, Matthew Steven Shaw, Zachary Rubnitz, Jarrod Smith, Heloisa P Soares
JAMA Network Open. 2025-01-02 - Reply to 'NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3'.Christopher Nevala-Plagemann, Thierry Conroy, Ignacio Garrido-Laguna
Nature Reviews. Clinical Oncology. 2024-12-01
Grant Support
- THE OHIO STATE UNIVERSITY AS A LEAD ACADEMIC ORGANIZATION (LAO) FOR THE EXPERIMENTAL THERAPEUTICS CLINICAL TRIALS NETWORKNCI2020–2025
- Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic CancerNCIPresent
Committees
- Member, GI committee SWOG 2014 - Present
Professional Memberships
- European Society of Medical OncologyMember
- Spanish Society of Medical OncologyMember
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
